Abstract
The widespread distribution of endothelin receptors and the suspected role of the endothelins are discussed thoroughly in previous and subsequent chapters. With the exception of issues of teratology, surprisingly few adverse effects secondary to administration of endothelin receptor antagonists have been reported in pre-clinical trials in experimental animals. Similarly, relatively few adverse effects have been reported in clinical trials in healthy volunteers or patients. The reader should be appropriately skeptical, however, as endothelin antagonists are relatively new therapeutic entities and, as such, their toxicity spectrum could be broader and deeper than the literature would suggest at this point in time. Only wider preclinical and clinical experience can answer such questions.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Barni T, Maggi M, Fantoni G, Serio M, Tollaro I, Gloria L, Vannelli GB (1995) Identification and localization of endothelin-1 and its receptors in human fetal jaws. Dev Biol 169:373–377
Cloutheir DE, Hosoda K, Richardson JA, Williams SC, Yanaglsawa H, Kuwaki T, Kumada, M, Hammer RE, Yanagisawa M (1998) Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 125:813–824
Dogterom P, Zbinden G (1992) Cardiotoxicity of vasodilators and positive inotrophic/vasodilating drugs in dogs: an overview. Crit Rev Toxicol 22:203–241
Hosoda K, Hammer RE, Richardson JA, Baynash AG, Cheung JC, Giaid A, Yanagisawa M (1994) Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell (79):1267–1276
Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V(1998) The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension, N Engl J Med 338:784–790
Kunieda T, Kumagai T, Tsuji T, Ozaki T, Karaki H, Ikadae H (1996) A mutation in the endothelin-B receptor gene causes myenteric aganglionosis and coat color spotting in rats. DNA Res: 30(2):101–105
Kurihara Y, Kurihara H, Suzuki H, Dodama T, Maemura K, Nagai R, Oda H, Kusawki T, Cau W-H, Kamada N, Jishage K, Ouchi Y, Azuma S, Toyoda Y, Ishikawa T, Kumada M, Yazaki Y (1994) Elevated blood pressure and cranialfacial abnormalities in mice deficient in endothelin-1. Nature 368:703–710
Kurihara Y, Kurihara H, Oda H, Maemura K, Nagai, R, Ishikawa T, Yazaki Y (1995) Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. J Clin Invest 96:293–300
Louden C, Nambi P, Branch C, Gossett K, Pullen M, Eustis S, Solleveld HA (1998) Coronary arterial lesions in dogs treated with an endothelin receptor antagonist, J Cardiovasc Pharmacol 31[Suppl l]:S384–385
Mesfin GM, Piper RC, DuCharme DW, Carlson RG, Humphrey SJ, Zins GR (1989) Pathogenesis of cardiovascular alterations in dogs treated with minoxidil. Toxicol Pathol 17(1):164–181
Mesfin GM, Higgins MJ, Robinson FG, Wei-Zhu Z (1996) Relationship between serum concentrations, hemodynamic effects, and cardiovascular lesions in dogs treated with minoxidil. Toxicol Appl Pharamcol 140, 337–344
Metallinois DL, Bowling AT, Rine J (1998) A missense mutation in the endothelin-B receptor gene is associated with Lethal White Foal syndrome: an equine version of Hirschsprung disease. Mamm Genome 9(6):426–431
Rhoten RL, Comair YG, Shedid D, Chyatte D, Simonson MS (1997) Specific repression of the preproendothelin-1 gene in intracranial arteriovenous malformations. J Neurosurg 86(1):101–108
Robertson K, Mason I, Hall S (1997) Hirschsprung’s disease: genetic mutations in mice and men. Gut 41(4):436–441
Sobota JT (1989) Review of cardiovascular findings in humans treated with minoxidil. Toxicol Pathol 17(1 Pt 2):193–202
Tsaur, ML, Wan YC, L FP, Cheng HF (1997) Expression of B-type endothelin receptor gene during neural development. FEBS Letters 417:208–212
Webb DJ and Strachan FE (1998) Clinical experience with endothelin antagonists, Am J Hypertens 11:71S-79S
Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marie SP, Peeters PAM, Jonkman JHG, Jones, C (1996) Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60:124–137
Yanagisawa H, Yangisawa M, Kapur RP, Richardson JA, Williams SC, Clotheir DE, deWit D, Emoto N, Hammer RE (1988) Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development 125:825–836
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Morgan, S.J., Cusick, P.K., Trela, B.A. (2001). Toxicology of Endothelin Antagonists. In: Warner, T.D. (eds) Endothelin and Its Inhibitors. Handbook of Experimental Pharmacology, vol 152. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56899-2_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-56899-2_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63237-2
Online ISBN: 978-3-642-56899-2
eBook Packages: Springer Book Archive